Cost effectiveness of adjuvant interferon in node-positive melanoma

Journal of Clinical Oncology

Volumn 25, Issue 17, 2007, Pages 2442-2448

  Cormier, Janice N ^a   Xing, Yan ^a   Ding, Meichun ^a   Cantor, Scott B ^a   Salter, Kristi J ^a   Lee, Jeffrey E ^a   Mansfield, Paul F ^a   Gershenwald, Jeffrey E ^a   Ross, Merrick I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; KEYHOLE LIMPET HEMOCYANIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LIFE EXPECTANCY; MELANOMA; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR;

CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; HUMANS; INTERFERONS; LYMPHATIC METASTASIS; MARKOV CHAINS; MELANOMA; MIDDLE AGED; MODELS, THEORETICAL; QUALITY OF LIFE;

EID: 34347221250     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.7284     Document Type: Article

References (40)

1. Balch CM, Soong S-J, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
2. Creagan ET, Dalton RJ, Ahmann DL, et al: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783, 1995
3. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996
4. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
5. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
6. Kirkwood JM, Ibrahim J, Lawson DH, et al: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II trial E2696. J Clin Oncol 19:1430-1436, 2001
7. Kirkwood JM, Manola J, Ibrahim J, et al: A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670-1677, 2004
8. Schuchter LM: Adjuvant interferon therapy for melanoma: High-dose, low-dose, no dose, which dose? J Clin Oncol 22:7-10, 2004
9. Moschos SJ, Kirkwood JM, Konstantinopoulos PA: Present status and future prospects for adjuvant therapy of melanoma: Time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 22:11-14, 2004
10. Grab JJ, Dreno B, de la Salmoniere P, et al: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases: French Cooperative Group on Melanoma. Lancet 351:1905-1910, 1998
11. Cascinelli N, Belli F, MacKie RM, et al: Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 358:866-869, 2001
12. Eggermont AMM, Kleeberg UR, Ruiter DJ, et al: The European Organisation for Research and Treatment of Cancer Melanoma Group trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b. Am Soc Clin Oncol Ed Book 2001, pp 88-93
13. Kirkwood JM, Bender C, Agarwala S, et al: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703-3718, 2002
14. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
15. Eggermont AMM, Keilholz U: What is the role of biological response modifiers in the treatment of melanoma? in Newton Bishop JA, Gore M (eds): Melanoma: Critical Debates. Oxford, Blackwell Science Ltd, 2002, pp 195-211
16. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
17. Cormier JN, Xing Y, Ross MI, et al: Interferon-alpha in high-risk melanoma patients. Expert Review of Pharmacoeconomics and Outcomes Research 4:667-676, 2004
18. Arias E: United States Life Tables, National Vital Statistics Reports (NVSS). Department of Health and Human Services Centers for Disease Control and Prevention, 2000, pp 1-42
19. Gold MR, Siegel JE, Russell LB: Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996
20. American Joint Committee on Cancer, in Greene FL, Page DL, Fleming ID, et al (eds): AJCC Cancer Staging Handbook (ed 6). New York, Springer, 2002, pp 421
21. Collett D: Modeling Survival Data in Medical Research. London, Chapman & Hall, 1994
22. Gerdtham UG, Zethraeus N: Predicting survival in cost-effectiveness analyses based on clinical trials. Int J Technol Assess Health Care 19:507-512, 2003
23. Siegel JE, Torrance GW, Russell LB, et al: Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Health and Medicine Pharmacoeconomics 11:159-168, 1997
24. Kilbridge KL, Weeks JC, Sober AJ, et al: Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19:812-823, 2001
25. Mooney MM, Mettlin C, Michalek AM, et al: Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: A cost-effectiveness analysis. Cancer 80:1052-1064, 1997
26. Hillner BE, Kirkwood JM: Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: Trade-offs between completeness, simplicity and clarity. Eur J Cancer 33:1345-1346, 1997
27. Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M, et al: Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer 36:2344-2352, 2000
28. Hillner BE, Kirkwood JM, Atkins MB, et al: Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 15:2351-2358, 1997
29. United States Department of Labor: Consumer Price Index Summary. US Bureau of Labor Statistics, 2006
30. Chang S, Long SR, Kutikova L, et al: Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 22:3524-3530, 2004
31. Hofmann U, Szedlak M, Rittgen W, et al: Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 87:151-157, 2002
32. Messori A, Becagli P, Trippoli S, et al: A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 33:1373-1379, 1997
33. Crott R, Ali F, Burdette-Radoux S: Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 7:423-432, 2004
34. Earle CC, Chapman RH, Baker CS, et al: Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302-3317, 2000
35. Laupacis A, Feeny D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Ca Med Assoc J 146:473-481, 1992
36. Birch S, Gafni A: The biggest bang for the buck or bigger bucks for the bang: The fallacy of the cost-effectiveness threshold. J Health Serv Res Policy 11:46-51, 2006
37. Ubel PA, Hirth RA, Chernew ME, et al: What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163:1637-1641, 2003
38. Glimelius B, Hoffman K, Graf W, et al: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 6:267-274, 1995
39. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al: Breast cancer screening and cost-effectiveness: Policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 49:531-537, 1991
40. Zbrozek AS, Cantor SB, Cardenas MP, et al: Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 51:1555-1563, 1994